Main-effect ORs for final stepwise logistic regression model of 7-day PPA, week 12
| Effect* | OR estimate | 95% lower CI | 95% upper CI | |
| Demographics | Age | 1.010 | 1.005 | 1.014 |
| BMI | 1.013 | 1.004 | 1.022 | |
| Black race (vs white) | 0.622 | 0.518 | 0.748 | |
| Psychiatric characteristics | Psychotic disorder | 0.605 | 0.435 | 0.841 |
| Use of psychiatric medications | 0.789 | 0.688 | 0.904 | |
| Smoking characteristics | FTND | 0.907 | 0.879 | 0.936 |
| Cigarettes per day | 0.968 | 0.960 | 0.976 | |
| Contact with smoker | 0.856 | 0.764 | 0.961 | |
| Prior varenicline | 1.228 | 1.060 | 1.422 | |
| Treatment group (vs placebo) | Varenicline | 3.808 | 3.260 | 4.447 |
| Bupropion | 2.059 | 1.755 | 2.417 | |
| NRT | 2.103 | 1.793 | 2.468 | |
| Region (vs North America I) | Eastern Europe | 0.390 | 0.222 | 0.686 |
| South America | 0.170 | 0.083 | 0.348 | |
| Western Europe | 1.356 | 1.140 | 1.613 | |
| Country-level variables | GDP† | 0.544 | 0.468 | 0.631 |
| Cigarette RIP | 0.617 | 0.528 | 0.722 | |
| MPOWER | 1.031 | 1.008 | 1.055 | |
*Only the most significant effects are shown.
†GDP per capita per US$10 000.
BMI, body mass index; FTND, Fagerström Test for Nicotine Dependence; GDP, gross domestic product; NRT, nicotine replacement therapy; PPA, point prevalence abstinence; RIP, relative income price.